Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis

V Kumar, X **n, J Ma, C Tan, N Osna… - Advanced drug delivery …, 2021‏ - Elsevier
Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …

Review on near-infrared heptamethine cyanine dyes as theranostic agents for tumor imaging, targeting, and photodynamic therapy

C Shi, JB Wu, D Pan - Journal of biomedical optics, 2016‏ - spiedigitallibrary.org
A class of near-infrared fluorescence (NIRF) heptamethine cyanine dyes that are taken up
and accumulated specifically in cancer cells without chemical conjugation have recently …

Sequential nano-penetrators of capillarized liver sinusoids and extracellular matrix barriers for liver fibrosis therapy

LF Zhang, XH Wang, CL Zhang, J Lee, BW Duan… - ACS …, 2022‏ - ACS Publications
During liver fibrogenesis, liver sinusoidal capillarization and extracellular matrix (ECM)
deposition construct dual pathological barriers to drug delivery. Upon capillarization, the …

Hyaluronan as a therapeutic target in human diseases

J Liang, D Jiang, PW Noble - Advanced Drug Delivery Reviews, 2016‏ - Elsevier
Accumulation and turnover of extracellular matrix is a hallmark of tissue injury, repair and
remodeling in human diseases. Hyaluronan is a major component of the extracellular matrix …

Hyaluronate and its derivatives for customized biomedical applications

H Kim, H Jeong, S Han, S Beack, BW Hwang, M Shin… - Biomaterials, 2017‏ - Elsevier
Since hyaluronate (HA) was firstly isolated from the vitreous of bovine eyes in 1934, HA has
been widely investigated for various biomedical applications. As a naturally-occurring …

Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells

S **a, Z Liu, J Cai, H Ren, Q Li, H Zhang, J Yue… - Journal of Controlled …, 2023‏ - Elsevier
Liver fibrosis is one of the most common liver diseases with substantial morbidity and
mortality. However, effective therapy for liver fibrosis is still lacking. Considering the key …

Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid

S Yin, J Huai, X Chen, Y Yang, X Zhang, Y Gan… - Acta biomaterialia, 2015‏ - Elsevier
Polymer–drug conjugates have demonstrated application potentials in optimizing
chemotherapeutics. In this study a new bioconjugate, HA-ss-PTX, was designed and …

Hyaluronic acid derivatives for translational medicines

H Kim, M Shin, S Han, W Kwon, SK Hahn - Biomacromolecules, 2019‏ - ACS Publications
The recent progress in various biomaterials with unique physiological and pharmacological
properties has expedited the development of translational medicines for the diagnosis …

Hyaluronate Epidermal Growth Factor Conjugate for Skin Wound Healing and Regeneration

H Kim, WH Kong, KY Seong, DK Sung… - …, 2016‏ - ACS Publications
Epidermal growth factor (EGF) has been recognized as an excellent wound healing agent
due to its therapeutic function stimulating skin cell growth, proliferation and differentiation …

Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis

Z Chen, A Jain, H Liu, Z Zhao, K Cheng - The Journal of Pharmacology and …, 2019‏ - Elsevier
Liver fibrosis is caused by excessive accumulation of extracellular matrix during chronic liver
injuries. Although clinical evidence suggests that liver fibrosis can be reversed, there is no …